Literature DB >> 82604

Mechanism of action of factor D of the alternative complement pathway.

P H Lesavre, H J Müller-Eberhard.   

Abstract

Factor D (C3 proactivator convertase) of human serum has been shown to be absolutely necessary for alternative pathway function, for activation of the C3/C5 convertase of that pathway and not to be a subunit of this enzyme. Factor D was found to be present in human plasma in active form only, at a concentration of 2 microgram/ml, and not to be controlled by plasma protease inhibitors or by spontaneous decay. Unlike trypsin, factor D cleaves and activates factor B only when it is in Mg++-dependent complex with C3b, has no esterolytic activity, and is unable to cleave the B chain of insulin. The alleged functional and antigenic relationship of factor D to alpha-thrombin could not be verified. The results of this study led to the description of the mechanism of action of factor D in terms of the cryptic site hypothesis.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 82604      PMCID: PMC2185104          DOI: 10.1084/jem.148.6.1498

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  35 in total

1.  Formation and composition of the C3 activating enzyme complex of the properdin system. Sequential assembly of its components on solid-phase trypsin-agarose.

Authors:  W Vogt; G Schmidt; L Dieminger; R Lynen
Journal:  Z Immunitatsforsch Exp Klin Immunol       Date:  1975-07

2.  FURTHER STUDIES ON THE PURIFICATION AND CHARACTERIZATION OF HUMAN PLASMINOGEN AND PLASMIN.

Authors:  K C ROBBINS; L SUMMARIA; D ELWYN; G H BARLOW
Journal:  J Biol Chem       Date:  1965-01       Impact factor: 5.157

3.  Measurement of the rate of plasmin action on synthetic substrates.

Authors:  P S ROBERTS
Journal:  J Biol Chem       Date:  1958-05       Impact factor: 5.157

4.  Isolation of alternative pathway C3 convertase containing uncleaved B and formed in the presence of C3 nephritic factor (C3neF).

Authors:  M R Daha; D T Fearon; K F Austen
Journal:  J Immunol       Date:  1976-02       Impact factor: 5.422

5.  Plasminogen and plasmin.

Authors:  K C Robbins; L Summaria
Journal:  Methods Enzymol       Date:  1976       Impact factor: 1.600

6.  Purification and some properties of factor D of the human properdin system.

Authors:  L Dieminger; W Vogt; R Lynen
Journal:  Z Immunitatsforsch Immunobiol       Date:  1976-11

7.  Regulation by membrane sialic acid of beta1H-dependent decay-dissociation of amplification C3 convertase of the alternative complement pathway.

Authors:  D T Fearon
Journal:  Proc Natl Acad Sci U S A       Date:  1978-04       Impact factor: 11.205

8.  Properdin: initiation of alternative complement pathway.

Authors:  D T Fearon; K F Austen
Journal:  Proc Natl Acad Sci U S A       Date:  1975-08       Impact factor: 11.205

9.  Properdin- and nephritic factor-dependent C3 convertases: requirement of native C3 for enzyme formation and the function of bound C3b as properdin receptor.

Authors:  R D Schreiber; R G Medicus; O Gïtze; H J Müller-Eberhard
Journal:  J Exp Med       Date:  1975-09-01       Impact factor: 14.307

10.  ISOLATION OF BETA IF-GLOBULIN FROM HUMAN SERUM AND ITS CHARACTERIZATION AS THE FIFTH COMPONENT OF COMPLEMENT.

Authors:  U R NILSSON; H J MUELLER-EBERHARD
Journal:  J Exp Med       Date:  1965-08-01       Impact factor: 14.307

View more
  48 in total

1.  Inhibiting alternative pathway complement activation by targeting the factor D exosite.

Authors:  Kenneth J Katschke; Ping Wu; Rajkumar Ganesan; Robert F Kelley; Mary A Mathieu; Philip E Hass; Jeremy Murray; Daniel Kirchhofer; Christian Wiesmann; Menno van Lookeren Campagne
Journal:  J Biol Chem       Date:  2012-02-23       Impact factor: 5.157

2.  Manduca sexta hemolymph proteinase 21 activates prophenoloxidase-activating proteinase 3 in an insect innate immune response proteinase cascade.

Authors:  Maureen J Gorman; Yang Wang; Haobo Jiang; Michael R Kanost
Journal:  J Biol Chem       Date:  2007-02-22       Impact factor: 5.157

3.  Essential role of complement mannose-binding lectin-associated serine proteases-1/3 in the murine collagen antibody-induced model of inflammatory arthritis.

Authors:  Nirmal K Banda; Minoru Takahashi; Brandt Levitt; Magdalena Glogowska; Jessica Nicholas; Kazue Takahashi; Gregory L Stahl; Teizo Fujita; William P Arend; V Michael Holers
Journal:  J Immunol       Date:  2010-09-24       Impact factor: 5.422

4.  Calcium-independent haemolysis via the lectin pathway of complement activation in the guinea-pig and other species*.

Authors:  Y Zhang; C Suankratay; X Zhang; D R Jones; T F Lint; H Gewurz
Journal:  Immunology       Date:  1999-08       Impact factor: 7.397

5.  Activation of the alternative and classical complement pathways by Entamoeba histolytica.

Authors:  J Calderon; R D Schreiber
Journal:  Infect Immun       Date:  1985-11       Impact factor: 3.441

6.  Induction of immune cytolysis: tumor-cell killing by complement is initiated by covalent complex of monoclonal antibody and stable C3/C5 convertase.

Authors:  C W Vogel; H J Müller-Eberhard
Journal:  Proc Natl Acad Sci U S A       Date:  1981-12       Impact factor: 11.205

7.  Mutations of factor H impair regulation of surface-bound C3b by three mechanisms in atypical hemolytic uremic syndrome.

Authors:  Markus J Lehtinen; Angelique L Rops; David E Isenman; Johan van der Vlag; T Sakari Jokiranta
Journal:  J Biol Chem       Date:  2009-04-07       Impact factor: 5.157

8.  Complement activation in patients with renal failure as detected through the quantitation of fragments of the complement proteins C3, C5, and factor B.

Authors:  M Oppermann; M Haubitz; E Quentin; O Götze
Journal:  Klin Wochenschr       Date:  1988-09-15

9.  The activation of the alternative pathway C3 convertase by human plasma kallikrein.

Authors:  R G DiScipio
Journal:  Immunology       Date:  1982-03       Impact factor: 7.397

10.  Alternative pathway-mediated rebinding of immune complexes to human red blood cells.

Authors:  M E Medof; G M Prince
Journal:  Immunology       Date:  1983-09       Impact factor: 7.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.